1. Home
  2. PRFX vs SHPH Comparison

PRFX vs SHPH Comparison

Compare PRFX & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$0.89

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

HOLD

Current Price

$2.00

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRFX
SHPH
Founded
2007
2012
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
2.9M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
PRFX
SHPH
Price
$0.89
$2.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
95.3K
264.2K
Earning Date
02-27-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$1.26
52 Week High
$6.65
$25.25

Technical Indicators

Market Signals
Indicator
PRFX
SHPH
Relative Strength Index (RSI) 49.84 51.22
Support Level $0.66 $1.79
Resistance Level $0.74 $2.02
Average True Range (ATR) 0.06 0.24
MACD 0.01 0.04
Stochastic Oscillator 74.46 27.03

Price Performance

Historical Comparison
PRFX
SHPH

About PRFX PainReform Ltd.

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

Share on Social Networks: